Testing for liver-related autoantibodies should be included in the workup of patients with
hepatitis or cholestasis of unknown origin. Although most of these autoantibodies are not …

Diseases involving the hepatopancreatobiliary (HPB) system are frequently encountered in
patients with inflammatory bowel disease (IBD). Hepatobiliary manifestations constitute …

Background There is no satisfactory medical therapy for patients with primary sclerosing
cholangitis. Ursodiol (ursodeoxycholic acid) benefits patients with primary biliary cirrhosis …

Metabolic processes utilize a variety of differing and contrasting biochemical routes to
enable synthesis of degradation and activation or deactivation of substances; in addition …

Extraintestinal manifestations in patients withinflammatory bowel disease (IBD) are quite
common (about25%) and careful clinical observation and statisticalanalysis during the last …

The aetiology of primary sclerosing cholangitis (PSC) is not known and controversy exists as
to whether PSC should be denominated an autoimmune disease. A large number of …

The pathogenesis of Crohn′ s disease (CD) and ulcerative colitis (UC), the two main forms
of inflammatory bowel disease (IBD), is still unclear, but both autoimmune and immune …

The liver is an important immunological organ that controls systemic tolerance. The liver
harbors professional and unconventional antigen-presenting cells that are crucial for …

Background: Only a few studies have attempted to determine the prevalence of long-
standing abnormal liver function and primary sclerosing cholangitis (PSC) in patients with …

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, characterized by
progressive inflammation and fibrosis of the bile ducts, resulting in biliary cirrhosis and is …